TY - JOUR
T1 - Gut bacterial profiles in Parkinson's disease
T2 - A systematic review
AU - Li, Zhe
AU - Liang, Hongfeng
AU - Hu, Yingyu
AU - Lu, Lin
AU - Zheng, Chunye
AU - Fan, Yuzhen
AU - Wu, Bin
AU - Zou, Tao
AU - Luo, Xiaodong
AU - Zhang, Xinchun
AU - Zeng, Yan
AU - Liu, Ziyan
AU - Zhou, Zhicheng
AU - Yue, Zhenyu
AU - Ren, Yi
AU - Li, Zhuo
AU - Su, Qiaozhen
AU - Xu, Pingyi
N1 - Funding Information:
This work was supported by the National Key Research and Development Projects of China (2016YFC1306601, 2017YFC1310300), the National Natural Science Foundation of China (81373712, 81873358, 81870992, 82004459), the Nature Science Foundation of Guangdong Province (2018A030310521), Research Project of Traditional Chinese Medicine Bureau of Guangdong Province (20221160), the Science and Technology Planning Project of Guangzhou (201604020152, 201803040020), Research Fund for Zhaoyang Talents of Guangdong Provincial Hospital of Chinese Medicine (ZY2022KY09). We thank AJE ( www.aje.com ) for linguistic assistance.
Publisher Copyright:
© 2022 The Authors. CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.
PY - 2023/1
Y1 - 2023/1
N2 - Introduction: Recent advances have highlighted the relationships between gut dysbiosis and Parkinson's disease (PD). Microbiota transplantation from PD patients to mice can induce increased alpha-synuclein-mediated motor deficits. Human studies have identified differences in the gut microbiota of PD patients compared to healthy controls. We undertook a systematic review to evaluate the available evidence for the involvement of gut bacteria in the etiology of PD. Methods: The PubMed databank, the China National Knowledge Infrastructure databank, and Wanfang Data were searched from inception until June 2021 to identify human case–control studies that investigated relationships between PD and microbiota quantified from feces. We evaluated the resulting studies focusing on bacterial taxa that were different between PD patients and healthy controls. Results: Twenty-six studies were found in which 53 microbial families and 98 genera exhibited differences between patients with PD and healthy controls. The genera identified by more than two studies as increased in PD were Bifidobacterium, Alistipes, Christensenella, Enterococcus, Oscillospira, Bilophila, Desulfovibrio, Escherichia/Shigella, and Akkermansia, while Prevotella, Blautia, Faecalibacterium, Fusicatenibacter, and Haemophilus had three or more reports of being lower in PD patients. More than one report demonstrated that Bacteroides, Odoribacter, Parabacteroides, Butyricicoccus, Butyrivibrio, Clostridium, Coprococcus, Lachnospira, Lactobacillus, Megasphaera, Phascolarctobacterium, Roseburia, Ruminococcus, Streptococcus, and Klebsiella were altered in both directions. Conclusion: Our review shows that the involvement of the gut microbiome in the etiology of PD may involve alterations of short-chain fatty acids (SCFAs)-producing bacteria and an increase in putative gut pathobionts. SCFAs-producing bacteria may vary above or below an “optimal range,” causing imbalances. Considering that Bifidobacterium, Lactobacillus, and Akkermansia are beneficial for human health, increased Bifidobacterium and Lactobacillus in the PD gut microbiome may be associated with PD medications, especially COMT inhibitors, while a high level of Akkermansia may be associated with aging.
AB - Introduction: Recent advances have highlighted the relationships between gut dysbiosis and Parkinson's disease (PD). Microbiota transplantation from PD patients to mice can induce increased alpha-synuclein-mediated motor deficits. Human studies have identified differences in the gut microbiota of PD patients compared to healthy controls. We undertook a systematic review to evaluate the available evidence for the involvement of gut bacteria in the etiology of PD. Methods: The PubMed databank, the China National Knowledge Infrastructure databank, and Wanfang Data were searched from inception until June 2021 to identify human case–control studies that investigated relationships between PD and microbiota quantified from feces. We evaluated the resulting studies focusing on bacterial taxa that were different between PD patients and healthy controls. Results: Twenty-six studies were found in which 53 microbial families and 98 genera exhibited differences between patients with PD and healthy controls. The genera identified by more than two studies as increased in PD were Bifidobacterium, Alistipes, Christensenella, Enterococcus, Oscillospira, Bilophila, Desulfovibrio, Escherichia/Shigella, and Akkermansia, while Prevotella, Blautia, Faecalibacterium, Fusicatenibacter, and Haemophilus had three or more reports of being lower in PD patients. More than one report demonstrated that Bacteroides, Odoribacter, Parabacteroides, Butyricicoccus, Butyrivibrio, Clostridium, Coprococcus, Lachnospira, Lactobacillus, Megasphaera, Phascolarctobacterium, Roseburia, Ruminococcus, Streptococcus, and Klebsiella were altered in both directions. Conclusion: Our review shows that the involvement of the gut microbiome in the etiology of PD may involve alterations of short-chain fatty acids (SCFAs)-producing bacteria and an increase in putative gut pathobionts. SCFAs-producing bacteria may vary above or below an “optimal range,” causing imbalances. Considering that Bifidobacterium, Lactobacillus, and Akkermansia are beneficial for human health, increased Bifidobacterium and Lactobacillus in the PD gut microbiome may be associated with PD medications, especially COMT inhibitors, while a high level of Akkermansia may be associated with aging.
KW - Parkinson's disease
KW - family
KW - genus
KW - gut bacteria
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85140402712&partnerID=8YFLogxK
U2 - 10.1111/cns.13990
DO - 10.1111/cns.13990
M3 - Article
C2 - 36284437
AN - SCOPUS:85140402712
SN - 1755-5930
VL - 29
SP - 140
EP - 157
JO - CNS Neuroscience and Therapeutics
JF - CNS Neuroscience and Therapeutics
IS - 1
ER -